查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1631177

Gabapentin市場規模、佔有率、趨勢分析報告：按劑型、類型、應用、分銷管道、地區、細分預測，2025-2030 年

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

Gabapentin市場成長與趨勢

根據Grand View Research, Inc.的最新報告，全球Gabapentin市場規模預計到2030年將達到30.7億美元，2025年至2030年期間的複合年成長率為5.2%。

這種成長是由於Gabapentin在治療神經病變疼痛方面的使用量不斷增加，以及癲癇等相關疾病的全球發病率不斷上升所致。另一個主要的成長要素是老年人口的增加，他們更容易患癲癇和神經性疼痛等疾病。

學名藥需求的不斷成長為大型學名藥製造商創造了機會，但由於對學名藥的偏好較高，中低收入國家的機會更為有利可圖。此外，北美和歐洲等已開發地區正在進行政策變化，透過推廣使用Gabapentin等學名藥來減輕其醫療系統的負擔。

Gabapentin主要有三種劑型：錠劑、膠囊和口服液。由於領先品牌產品的存在和易於獲得，膠囊在 2022 年佔據了最大的市場佔有率。Gabapentin被發現有成癮和過量攝取的風險，導致一些國家對其使用進行嚴格審查和限制。這些發現可能會影響Gabapentin的長期成長，促使藥廠專注於開發更安全、更有效的止痛藥。

由於北美發達的醫療保健體系鼓勵採用Gabapentin等藥物，預計北美將在預測期內佔據市場主導地位。然而，由於主要學名藥參與企業的出現，以及人們對採用藥物治療方法而非亞洲國家主要使用的傳統治療方法的認知不斷提高，亞太地區等其他地區正在以更快的速度成長。

Gabapentin產業的主要競爭對手包括 Sun Pharmaceutical Industries Ltd.、Ascend Laboratories, LLC、Apotex Inc.、Teva Pharmaceutical Industries Ltd.、Arbor Pharmaceuticals, Inc. 和 Pfizer Inc.隨著品牌產品的衰落，競爭正在轉向非專利產品。這導致市場對參與企業和新產品的飽和狀態，從而導致競爭對手之間的敵意加劇。

Gabapentin市場報告重點

  • 膠囊將佔據市場主導地位，到 2024 年將佔 56.1% 的佔有率。這是因為它易於管理，使其成為包括兒童和老人在內的患者的理想選擇。
  • 仿製學名藥Gabapentin佔據市場主導地位，2024 年的銷售佔有率為 90.1%。學名藥提供了比品牌藥更具成本效益的替代品，擴大了更廣泛患者獲得藥物的管道。
  • 癲癇應用在 2024 年佔據了 49.9% 的最大市場佔有率，因為它被證明是一種抗驚厥藥物，對於癲癇患者的癲癇發作管理至關重要。
  • 醫院藥局佔據市場主導地位，到 2024 年將佔 47.6% 的佔有率。這是因為它是治療癲癇和神經病變疼痛等慢性疾病的重要醫療中心。
  • 北美Gabapentin市場佔據全球市場主導地位，2024 年的銷售佔有率為 33.7%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章Gabapentin市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

第4章Gabapentin市場：劑型業務分析

  • 2024 年及 2030 年劑型市場佔有率
  • 劑型細分細分儀表板
  • 2018-2030 年劑型市場規模、預測及趨勢分析
  • 錠劑
  • 膠囊
  • 口服液

第 5 章Gabapentin市場：類型業務分析

  • 2024 年及 2030 年類型市場佔有率
  • 類型細分儀表板
  • 2018 年至 2030 年按類型分類的市場規模、預測與趨勢分析
  • 非專利的
  • 品牌

第6章Gabapentin市場：應用業務分析

  • 2024 年和 2030 年應用市場佔有率
  • 應用程式細分儀表板
  • 2018 年至 2030 年按應用分類的市場規模、預測與趨勢分析
  • 癲癇
  • 神經病變疼痛
  • 不寧腿
  • 其他

第7章Gabapentin市場：分銷通路業務分析

  • 分銷通路市場佔有率，2024 年和 2030 年
  • 分銷通路細分儀表板
  • 2018 年至 2030 年按分銷管道分類的市場規模、預測和趨勢分析
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 8 章Gabapentin市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區，2018 年至 2030 年
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區，2018 年至 2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Zydus Pharmaceuticals, Inc.
    • GLENMARK PHARMACEUTICALS LTD.
    • Sun Pharmaceutical Industries Ltd.
    • Ascend Laboratories LLC
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd
    • Aurobindo Pharma
    • Amneal Pharmaceuticals LLC.
    • Cipla
    • BP Pharma
    • Assertio Holdings, Inc.
    • Arbor Pharmaceuticals, LLC（Azurity Pharmaceuticals, Inc.）
    • Pfizer Inc.
Product Code: GVR-4-68040-043-6

Gabapentin Market Growth & Trends:

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising usage of gabapentin for neuropathic pain and the increasing incidence of associated diseases such as epilepsy globally. The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.

The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.

Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.

North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.

Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.

Gabapentin Market Report Highlights:

  • Capsules dominated the market and accounted for a share of 56.1% in 2024. This is attributed to their ease of administration, which makes them ideal for patients, including children and the elderly.
  • Generic gabapentin led the market with a revenue share of 90.1% in 2024. Generics provide a cost-effective alternative to branded medications, expanding accessibility for a wider patient demographic.
  • Applications in epilepsy held the largest market share of 49.9% in 2024, owing to its proven efficacy as an anticonvulsant essential for seizure management in individuals with epilepsy.
  • Hospital pharmacies dominated the market and accounted for a share of 47.6% in 2024, serving as key healthcare facilities for treating chronic conditions such as epilepsy and neuropathic pain.
  • North America gabapentin market dominated the global market with a revenue share of 33.7% in 2024.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Dosage Form
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gabapentin Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gabapentin Market: Dosage Form Business Analysis

  • 4.1. Dosage Form Market Share, 2024 & 2030
  • 4.2. Dosage Form Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 4.4. Tablet
    • 4.4.1. Tablet Market, 2018 - 2030 (USD Million)
  • 4.5. Capsule
    • 4.5.1. Capsule Market, 2018 - 2030 (USD Million)
  • 4.6. Oral Solution
    • 4.6.1. Oral Solution Market, 2018 - 2030 (USD Million)

Chapter 5. Gabapentin Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Generic
    • 5.4.1. Generic Market, 2018 - 2030 (USD Million)
  • 5.5. Branded
    • 5.5.1. Branded Market, 2018 - 2030 (USD Million)

Chapter 6. Gabapentin Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Epilepsy
    • 6.4.1. Epilepsy Market, 2018 - 2030 (USD Million)
  • 6.5. Neuropathic Pain
    • 6.5.1. Neuropathic Pain Market, 2018 - 2030 (USD Million)
  • 6.6. Restless Legs Syndrome
    • 6.6.1. Restless Legs Syndrome Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Gabapentin Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Gabapentin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Zydus Pharmaceuticals, Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GLENMARK PHARMACEUTICALS LTD.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Sun Pharmaceutical Industries Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Ascend Laboratories LLC
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Apotex Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Teva Pharmaceutical Industries Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Aurobindo Pharma
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Amneal Pharmaceuticals LLC.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Cipla
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. B.P. Pharma
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Assertio Holdings, Inc.
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Arbor Pharmaceuticals, LLC (Azurity Pharmaceuticals, Inc.)
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Pfizer Inc.
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global gabapentin market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 5. Global gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 6. Global gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 7. Global gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 10. North America gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 11. North America gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 12. North America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 14. U.S. gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 15. U.S. gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 16. U.S. Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 18. Canada gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 19. Canada gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 20. Canada gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 22. Mexico gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 23. Mexico gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 24. Mexico gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 27. Europe gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 28. Europe gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 29. Europe gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 31. UK gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 32. UK gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 33. UK Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 35. Germany gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 36. Germany gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 37. Germany gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 39. France gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 40. France gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 41. France Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 43. Italy gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 44. Italy gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 45. Italy gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 47. Spain gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 48. Spain gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 49. Spain gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Norway gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 51. Norway gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 52. Norway gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 53. Norway Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Denmark gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 55. Denmark gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 56. Denmark gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 57. Denmark gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Sweden gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 59. Sweden gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 60. Sweden gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 61. Sweden gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Japan gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 68. Japan gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 69. Japan gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 70. Japan gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. China gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 72. China gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 73. China gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 74. China gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 76. India gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 77. India gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 78. India gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 80. Australia gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 81. Australia gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 82. Australia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 84. South Korea gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 85. South Korea gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Korea gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 88. Thailand gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 89. Thailand gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 90. Thailand gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 93. Latin America gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 94. Latin America gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 95. Latin America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 97. Brazil gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 98. Brazil gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 99. Brazil gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 101. Argentina gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 102. Argentina gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 103. Argentina gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Gabapentin market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 110. South Africa gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 111. South Africa gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 112. South Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 118. UAE gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 119. UAE gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 120. UAE gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait gabapentin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 122. Kuwait gabapentin market, by type, 2018 - 2030 (USD Million)
  • Table 123. Kuwait gabapentin market, by application, 2018 - 2030 (USD Million)
  • Table 124. Kuwait gabapentin market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gabapentin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Dosage form and type outlook (USD Million)
  • Fig. 10 Application and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Gabapentin market dynamics
  • Fig. 13 Gabapentin market: Porter's five forces analysis
  • Fig. 14 Gabapentin market: PESTLE analysis
  • Fig. 15 Gabapentin market: Dosage form segment dashboard
  • Fig. 16 Gabapentin market: Dosage form market share analysis, 2024 & 2030
  • Fig. 17 Tablet market, 2018 - 2030 (USD Million)
  • Fig. 18 Capsule market, 2018 - 2030 (USD Million)
  • Fig. 19 Oral solution market, 2018 - 2030 (USD Million)
  • Fig. 20 Gabapentin market: Type segment dashboard
  • Fig. 21 Gabapentin market: Type market share analysis, 2024 & 2030
  • Fig. 22 Generic market, 2018 - 2030 (USD Million)
  • Fig. 23 Branded market, 2018 - 2030 (USD Million)
  • Fig. 24 Gabapentin market: Application segment dashboard
  • Fig. 25 Gabapentin market: Application market share analysis, 2024 & 2030
  • Fig. 26 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 27 Neuropathic pain market, 2018 - 2030 (USD Million)
  • Fig. 28 Restless legs syndrome market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Gabapentin market: Distribution channel segment dashboard
  • Fig. 31 Gabapentin market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 32 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 33 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 34 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 35 Gabapentin market revenue, by region
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. country dynamics
  • Fig. 40 U.S. gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 41 Canada country dynamics
  • Fig. 42 Canada gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico country dynamics
  • Fig. 44 Mexico gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 46 UK country dynamics
  • Fig. 47 UK gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany country dynamics
  • Fig. 49 Germany gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 50 France country dynamics
  • Fig. 51 France gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy country dynamics
  • Fig. 53 Italy gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 54 Spain country dynamics
  • Fig. 55 Spain gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 56 Norway country dynamics
  • Fig. 57 Norway gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden country dynamics
  • Fig. 59 Sweden gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 60 Denmark country dynamics
  • Fig. 61 Denmark gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 63 Japan country dynamics
  • Fig. 64 Japan gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 65 China country dynamics
  • Fig. 66 China gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 67 India country dynamics
  • Fig. 68 India gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 69 Australia country dynamics
  • Fig. 70 Australia gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand country dynamics
  • Fig. 74 Thailand gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil country dynamics
  • Fig. 77 Brazil gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina country dynamics
  • Fig. 79 Argentina gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 80 MEA gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 81 South Africa country dynamics
  • Fig. 82 South Africa gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia country dynamics
  • Fig. 84 Saudi Arabia gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 85 UAE country dynamics
  • Fig. 86 UAE gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 87 Kuwait country dynamics
  • Fig. 88 Kuwait gabapentin market, 2018 - 2030 (USD Million)
  • Fig. 89 Company categorization
  • Fig. 90 Company market position analysis
  • Fig. 91 Strategic framework